Nigeria

Resilience System


You are here

Public Health

Iceland: Countering the pandemic, bringing life back to normal

While the rest of the world grapples with mass vaccinations and fear of the new coronavirus variants, life in Iceland is getting closer to normal.

Since the beginning of the month, not a single person has been diagnosed with Covid-19 domestically apart from a handful of people who were already in quarantine.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

NIH to launch research into Covid long term effects, plus international roundup

Roundup:  NIH to study ‘long-haul’ virus symptoms

  WASHINGTON  (AP) — The National Institutes of Health is launching research to understand the causes and consequences of the lingering brain fog, breathing problems and malaise reported by many recovering COVID-19 patients.

Dr. Anthony Fauci says some studies have shown up to 30% of patients report symptoms that can endure for months, complicating their return to normal routines and work, and plunging many recovering patients into depression.

Fauci noted at a White House coronavirus briefing on Wednesday that work at NIH started this week thanks to more than $1 billion provided by Congress for COVID-related medical research. Government scientists are looking to enlist doctors and research institutions around the country in the effort to learn about “long-haul” COVID-19.

Problem, Solution, SitRep, or ?: 

ANALYSIS" The need for global access to COVID-19 vaccines: production, affordability, allocation, and deployment

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.

In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. ...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Public Health
howdy folks
Page loaded in 2.145 seconds.